HC Wainwright reaffirmed their buy rating on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research ...

In a report released on February 7, Heiko Ihle from H.C. Wainwright reiterated a Buy rating on UR-Energy (URG – Research Report), with a price ...

H.C. Wainwright reiterated a Buy rating and a price target of $18.00 on Enanta Pharmaceuticals (NASDAQ:ENTA) shares, significantly above the current price of $4.90. The stock is trading near its ...

H.C. Wainwright increased its price target on Corcept Therapeutics (NASDAQ:CORT) shares to $115 from the previous $80, while ...

HC Wainwright reissued their buy rating on shares of Immix Biopharma (NASDAQ:IMMX – Free Report) in a report released on ...

H.C. Wainwright raised the firm’s price target on NextTrip (NTRP) to $5 from $2.50 and keeps a Neutral rating on the shares after the company ...

The company posted quarterly adjusted earnings of $3.48 per share which missed the analyst consensus estimate of $4.03 per ...

The aggregate gross proceeds to the Company from the offering are expected to be approximately $1.05 million, before ...

CEO Dhruv Shringi reported a 113% year-over-year increase in revenue from operations to INR 2.35 billion for Q3 2025, driven by strong performance in the Hotels and Packages and Corporate Travel ...

Langan reaffirmed the company’s five-year capital allocation strategy, aiming for $400 million in revenue and $75 million in free cash flow by FY29. The plan focuses on growing free cash flow per ...